A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
about
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionTherapeutic drug monitoring of antiretrovirals for people with HIVAntiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionThree- or four- versus two-drug antiretroviral maintenance regimens for HIV infectionImproved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimensA randomized double-blind study of the effect of distant healing in a population with advanced AIDS. Report of a small scale study.Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cellsContribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infectionLatent reservoirs of HIV: obstacles to the eradication of virusTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesAn Increased Risk of Osteoporosis during Acquired Immunodeficiency SyndromeAbacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensDeterminants of patient recruitment in a multicenter clinical trials group: trends, seasonality and the effect of large studiesGranulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection.Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual questionSTART or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus InfectionHIV-1 eradication strategies: design and assessmentDiscovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous Heterosubtypic Targeting that Hedge against Antiviral ResistanceEfficient Virus Extinction by Combinations of a Mutagen and Antiviral InhibitorsResponse of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivitySynthesis, X-ray Analysis, and Biological Evaluation of a New Class of Stereopure Lactam-Based HIV-1 Protease InhibitorsTreatment of CMV retinitis with intravitral ganciclovir in the HAART eraA potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agentsIn vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavirDPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitroACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAARTResistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integraseGenotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.ABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseCharacterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitroTreatment for human immunodeficiency virus with indinavir may cause relevant urological side-effects, effectively treatable by rehydrationInhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivativeDicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.An Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal EffectsViral and latent reservoir persistence in HIV-1-infected patients on therapyThe emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?"
P2860
Q24235500-1303A212-3AB9-4744-A7FD-277846CB7DEAQ24239932-00FDFF26-6D9B-4306-8FA7-5F50E7D5FD0FQ24243146-CF67ECEE-4AB8-4C0F-A367-970FE8E11ED0Q24247767-39586BA7-461E-4F08-9C3B-3F7E2171517AQ24534391-0D01AD9B-B5F3-43C0-AF5B-276A00799427Q24538481-AF97DCE8-3F39-4C41-8769-5A78F89756C5Q24548940-4742D4E7-E466-4FF7-9BD5-0110BB9E0537Q24550678-3F67796E-33A6-4646-A25E-64296B2F2349Q24615570-BA33B924-8FC5-4C0A-B5C7-83AE86C0F378Q24656950-A25E9298-2A49-4F88-8E1C-8E4CC165581EQ24791238-F262A4C7-A018-4650-8627-5C72FD4ADA34Q24799351-5084B82A-042D-4CCC-8710-F7EBC76C66B7Q24800021-C7AD94DD-4A9C-48E2-82F1-7A7912F66BAAQ24814373-B0921645-5899-43F1-B4C1-756796FB0B09Q26741384-B3CE0805-E2FF-4120-B7D2-73A2FAF78AE8Q26753830-56E1BD36-62DB-4557-8E4E-5AA1E48C5212Q26864933-2CD4A9FD-12EF-408D-ABC9-E6F8920016AFQ27316994-0AC74528-3077-41FC-9F46-E360BD5717A6Q27469870-69C63704-EADF-4EB0-9A17-E78F49904BF7Q27470003-A926C54E-C218-4158-B763-ED4C4B84FA0EQ27677537-809EF41C-686C-49B2-8148-7B391812FA9FQ28262771-BFFE8923-85A4-4A4E-A806-9984314AA6CBQ28344457-0222F820-DBB8-4DCB-B21D-8532AD91A9CCQ28344472-998FDCE3-22B5-45D4-8422-E68B99525E2EQ28344594-2B330DE1-9809-4292-B174-3E569B913793Q28345258-01B7687C-8A18-47CD-84FB-C959DC590956Q28361560-67CFF26C-567B-4CCE-BF77-E6B623F523CEQ28362567-62B57650-7B68-4739-8FE1-53341779E528Q28362780-A11123BF-B2DD-47AA-A068-7B2690BEE277Q28367724-6F37C71D-C899-41D4-84B0-1F924394C1B6Q28368842-BB3EF42B-C216-49D9-95FA-E42A950CD547Q28369030-2E715E98-240D-4476-9A6C-964B16DAFCD7Q28369297-74FA767E-2A4F-4ECE-A324-6B91176074D8Q28371764-FF57826B-3500-4F43-9F95-0BC5E1482445Q28373548-1349A24A-5B09-4E81-8FE5-8D0DCE4012D2Q28376476-055D5EC0-0093-464A-95BA-F904E818DF70Q28379316-1FE4B09E-3B05-41F6-8E40-70C13C1BCE40Q28386534-F214843B-D417-46F8-B1A8-FF89E3507771Q28469057-FE9BF8EF-3045-448C-8B34-5E392BAD3EDEQ28469108-C5571766-2E46-4CC9-89F5-5D5040D6F1AB
P2860
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@ast
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@en
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@nl
type
label
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@ast
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@en
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@nl
prefLabel
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@ast
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@en
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@nl
P2093
P1476
A controlled trial of two nucl ...... l Trials Group 320 Study Team.
@en
P2093
Balfour HH Jr
Chodakewitz JA
Currier JS
Demeter LM
Eron JJ Jr
Feinberg JE
P304
P356
10.1056/NEJM199709113371101
P407
P577
1997-09-01T00:00:00Z